Guardant Health Inc

GHNASDAQ · USD
151.70USD0.00 (-2.05%)
2410

Guardant Health Inc (GH) Option Chain

Guardant Health Inc trades at $151.70, down 2.05%, with an IV Rank of 25.79%. This is low versus the past year, and the company carries a market cap of $20,523M in the Diagnostics & Research industry. On the Nov 20, 2026 chain, the at the money $150.00 strike shows calls at $4.50 / $8.00 and puts at $2.20 / $5.80, both carrying about $4.28 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $150.00 calls, at 52 contracts, and the $160.00 puts, at 333, as of Nov 13, 2026.

Read more

Tracking the GH option chain helps you see every strike and expiry on Guardant Health Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of GH options activity at a glance. Use our scanner to monitor the GH option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For GH stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where GH options are being actively traded, and where they are not.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
15.18301.9011.7011.7015.50140.00-7.71—4.000.004.0002,38084.82
28.55612.906.707.8011.40145.00-4.420.404.000.002.2005371.45
45.2147524.551.704.508.00150.00-1.122.205.800.004.0001,28554.79
62.223313.900.002.205.60155.00+2.184.608.003.303.0021,68737.78
76.7134032.250.000.104.40160.00+5.477.8011.508.301.353331,96123.29

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDiagnostics & Research
  • SectorHealthcare
  • IV Rank25.79% Low
  • Market cap (M$)20,523
  • 52 weeks high-20.60%
  • 52 weeks low103.49%
  • Analyst recommendationStrong Buy
    1.41
  • Target price$204.75
    34.97% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.68
  • EPS growth next 5 years53.72%

As of Nov 13, 2026